المؤلفون: Huang SJ; Division of Hematology, Vancouver General Hospital, University of British Columbia, Canada., Gerrie AS; Division of Hematology, Vancouver General Hospital, University of British Columbia, Canada; British Columbia Cancer - Vancouver, University of British Columbia, Vancouver, British Columbia, Canada., Young S; Pathology and Laboratory Medicine, British Columbia Cancer, University of British Columbia, Vancouver, British Columbia, Canada., Tucker T; Pathology and Laboratory Medicine, British Columbia Cancer, University of British Columbia, Vancouver, British Columbia, Canada., Bruyere H; Division of Pathology and Laboratory Medicine, Cytogenetics Laboratory, Vancouver General Hospital, University of British Columbia, Canada., Hrynchak M; Molecular Cytogenetic Laboratory, Royal Columbian Hospital, University of British Columbia, New Westminster, British Columbia, Canada., Galbraith P; British Columbia Cancer - Abbotsford, University of British Columbia, Abbotsford, British Columbia, Canada., Al Tourah AJ; British Columbia Cancer - Surrey, University of British Columbia, Surrey, British Columbia, Canada., Dueck G; British Columbia Cancer - Kelowna, University of British Columbia, Kelowna, British Columbia, Canada., Noble MC; Royal Columbian Hospital, New Westminster, British Columbia, Canada., Ramadan KM; St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada., Tsang P; Division of Hematology, Vancouver General Hospital, University of British Columbia, Canada; Richmond Hospital, Richmond, British Columbia, Canada., Hardy E; Tom McMurty & Peter Baerg Cancer Centre, Vernon Jubilee Hospital, Vernon, British Columbia, Canada., Sehn L; British Columbia Cancer - Vancouver, University of British Columbia, Vancouver, British Columbia, Canada., Toze CL; Division of Hematology, Vancouver General Hospital, University of British Columbia, Canada; British Columbia Cancer - Vancouver, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: ctoze@bccancer.bc.ca.

المصدر: Leukemia research [Leuk Res] 2020 Apr; Vol. 91, pp. 106335. Date of Electronic Publication: 2020 Feb 24.

نوع المنشور: Comparative Study; Journal Article

بيانات الدورية: Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5835 (Electronic) Linking ISSN: 01452126 NLM ISO Abbreviation: Leuk Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Hematopoietic Stem Cell Transplantation/*methods , Leukemia, Lymphocytic, Chronic, B-Cell/*therapy , Pyrazoles/*therapeutic use , Pyrimidines/*therapeutic use , Smith-Magenis Syndrome/*therapy, Adenine/analogs & derivatives ; Adult ; Aged ; Aged, 80 and over ; British Columbia ; Chromosome Deletion ; Chromosomes, Human, Pair 17/genetics ; Cyclophosphamide/therapeutic use ; Disease Management ; Doxorubicin/therapeutic use ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Male ; Middle Aged ; Neoplasm, Residual ; Piperidines ; Prednisone/therapeutic use ; Prognosis ; Recurrence ; Remission Induction ; Retrospective Studies ; Rituximab/therapeutic use ; Smith-Magenis Syndrome/diagnosis ; Smith-Magenis Syndrome/genetics ; Smith-Magenis Syndrome/mortality ; Survival Analysis ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine/analogs & derivatives ; Vidarabine/therapeutic use ; Vincristine/therapeutic use

SCR Disease Name: Chromosome 17 deletion

SCR Protocol: CHOP protocol; COP protocol 2

المؤلفون: Tantiworawit A; Leukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Power MM, Barnett MJ, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Abou-Mourad YR, Narayanan S, Broady RC, Forrest DL

المصدر: Leukemia & lymphoma [Leuk Lymphoma] 2012 Jul; Vol. 53 (7), pp. 1321-6. Date of Electronic Publication: 2012 Mar 05.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

مواضيع طبية MeSH: Blast Crisis/*therapy , Leukemia, Myeloid, Chronic-Phase/*therapy , Piperazines/*therapeutic use , Pyrimidines/*therapeutic use, Adult ; Aged ; Benzamides ; Blast Crisis/pathology ; Combined Modality Therapy ; Disease Progression ; Female ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Imatinib Mesylate ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Chronic-Phase/pathology ; Male ; Middle Aged ; Protein Kinase Inhibitors/therapeutic use ; Remission Induction ; Time Factors ; Transplantation, Homologous ; Treatment Outcome ; Young Adult

المؤلفون: Forrest DL; Leukemia/BMT Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada. dforrest@bccancer.bc.ca, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ, Shepherd JD, Nantel SH, Toze CL, Sutherland HJ, Song KW, Lavoie JC, Power MM, Abou-Mourad Y, Smith CA

المصدر: Leukemia research [Leuk Res] 2009 Feb; Vol. 33 (2), pp. 271-5. Date of Electronic Publication: 2008 Aug 31.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5835 (Electronic) Linking ISSN: 01452126 NLM ISO Abbreviation: Leuk Res Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy , Piperazines/*blood , Pyrimidines/*blood, Adult ; Benzamides ; Cytogenetic Analysis ; Drug Monitoring ; Female ; Fusion Proteins, bcr-abl/analysis ; Humans ; Imatinib Mesylate ; In Situ Hybridization, Fluorescence ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis ; Leukemia, Myeloid, Accelerated Phase ; Leukemia, Myeloid, Chronic-Phase ; Male ; Middle Aged ; Piperazines/administration & dosage ; Polymerase Chain Reaction ; Pyrimidines/administration & dosage ; Risk Assessment

المؤلفون: Lin Y; The Leukemia/BMT Program of British Columbia, the Division of Hematology, 950 West 10th Avenue, Room 3300, Vancouver, British Columbia V5Z 4E3, Canada., Bruyère H, Horsman DE, Pantzar T, Barnett MJ, Hogge DE, Nevill TJ, Nantel SH, Sutherland HJ, Toze CL, Shepherd JD, Lavoie JC, Song KW, Smith CA, Forrest DL

المصدر: Cancer genetics and cytogenetics [Cancer Genet Cytogenet] 2006 Oct 01; Vol. 170 (1), pp. 16-23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier/North-Holland Country of Publication: United States NLM ID: 7909240 Publication Model: Print Cited Medium: Print ISSN: 0165-4608 (Print) Linking ISSN: 01654608 NLM ISO Abbreviation: Cancer Genet Cytogenet Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoiesis*, Antineoplastic Agents/*therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*genetics , Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/*drug therapy , Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/*genetics , Piperazines/*therapeutic use , Pyrimidines/*therapeutic use, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Benzamides ; Female ; Humans ; Imatinib Mesylate ; Karyotyping ; Male ; Middle Aged ; Risk Factors